Literature DB >> 3931145

Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious subjects.

W F Seidel, S A Cohen, L Wilson, W C Dement.   

Abstract

Eighteen non-anxious volunteers underwent sleep recordings and daytime tests of sleepiness, performance, and mood while receiving, either alprazolam 0.5 mg b.i.d. or diazepam 5 mg b.i.d. for 7 consecutive days. Recordings and tests were done before treatment and on the 1st and 7th days of treatment. Nocturnal sleep changes were similar for both groups; there were no statistically significant changes in mood. However, levels of daytime sleepiness differed. Alprazolam subjects showed more daytime sedation than diazepam subjects on treatment day 1, but showed a significant decrease in Day 1-7 daytime sedation. Although diazepam subjects were less sedated at the onset, they showed no tolerance to this effect; thus by treatment day 7, the two groups did not differ in levels of daytime sleepiness. Results suggested that tolerance to alprazolam's sedative effects (which develops during the 1st week of treatment) may be separable from tolerance to its antianxiety effects (which develops after at least 4 weeks). As daytime sedation is common and potentially dangerous with most anxiolytics, selective tolerance to this side effect is highly desirable.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931145     DOI: 10.1007/bf00431806

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  Quantification of sleepiness: a new approach.

Authors:  E Hoddes; V Zarcone; H Smythe; R Phillips; W C Dement
Journal:  Psychophysiology       Date:  1973-07       Impact factor: 4.016

Review 2.  Psychomotor function and psychoactive drugs.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

3.  Alprazolam (Xanax, the Upjohn Company).

Authors:  R L Evans
Journal:  Drug Intell Clin Pharm       Date:  1981-09

Review 4.  Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

Authors:  G W Dawson; S G Jue; R N Brogden
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

5.  Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex.

Authors:  M Divoll; D J Greenblatt; H R Ochs; R I Shader
Journal:  Anesth Analg       Date:  1983-01       Impact factor: 5.108

6.  Role of drugs in traffic accidents.

Authors:  R Honkanen; L Ertama; M Linnoila; A Alha; I Lukkari; M Karlsson; O Kiviluoto; M Puro
Journal:  Br Med J       Date:  1980-11-15

7.  Benzodiazepines: a summary of pharmacokinetic properties.

Authors:  D J Greenblatt; R I Shader; M Divoll; J S Harmatz
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

Review 8.  Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action.

Authors:  J A Fawcett; H M Kravitz
Journal:  Pharmacotherapy       Date:  1982 Sep-Oct       Impact factor: 4.705

  8 in total
  10 in total

1.  Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance.

Authors:  Joshua A Lile; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2011-07-06       Impact factor: 4.492

2.  Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects.

Authors:  R B Smith; P D Kroboth
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 3.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

4.  Effects of 1 week administration of two benzodiazepines on the sleep and early daytime performance of normal subjects.

Authors:  J L Jurado; R Fernández-Mas; A Fernández-Guardiola
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Benzodiazepines and vigilance performance: a review.

Authors:  H S Koelega
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis.

Authors:  Christopher A Kosky; Anastasios Bonakis; Arthee Yogendran; Gihan Hettiarachchi; Paul I Dargan; Adrian J Williams
Journal:  J Clin Sleep Med       Date:  2016-11-15       Impact factor: 4.062

7.  Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.

Authors:  Kari Laine; Outi Ahokoski; Risto Huupponen; Jutta Hänninen; Sanna Palovaara; Jori Ruuskanen; Harry Björklund; Markku Anttila; Juha Rouru
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

8.  Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing.

Authors:  P D Kroboth; J W McAuley; R B Smith
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Vigilance impairment after a single dose of benzodiazepines.

Authors:  L Kozená; E Frantik; M Horváth
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

10.  Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.

Authors:  Ariadna Amador; Salvador Huitron-Resendiz; Amanda J Roberts; Theodore M Kamenecka; Laura A Solt; Thomas P Burris
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.